Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity.

Myelodysplastic syndromes (MDS) are clonal, neoplastic disorders of hematopoietic tissue that convey a guarded prognosis, but physicians vary in whether they refer to MDS as a "cancer" when discussing the diagnosis with patients. Because of past ambiguity about whether MDS is truly a malignancy, confusion about MDS terminology is widespread. Additionally, patients who carry one of the dubious cancer-specific health insurance policies are usually not eligible for financial benefits when they receive a diagnosis of MDS. Likewise, patients with MDS who have been led to believe they do not have a form of cancer by their primary physician may become upset when seeing another health care provider who does refer to MDS in this way. Here, I discuss evidence supporting broader consideration of MDS as a form of malignant neoplasia - i.e., cancer - as well as some of the relevant practical issues.

[1]  J. Winter,et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study , 2005, Annals of Hematology.

[2]  N. Gattermann,et al.  Two types of acquired idiopathic sideroblastic anaemia (AISA) , 1990, British journal of haematology.

[3]  J. Bennett,et al.  Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. , 2002, Blood.

[4]  A. Burnett,et al.  Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34+ Cells , 1997, The Journal of experimental medicine.

[5]  B L Lambert,et al.  Predicting look-alike and sound-alike medication errors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  J. Pedersen‐Bjergaard,et al.  Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. , 1995, Blood.

[7]  S. Giralt.  Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. , 2004, Current hematology reports.

[8]  C. P. Rhoads,et al.  REFRACTORY ANEMIA: ANALYSIS OF ONE HUNDRED CASES , 1938 .

[9]  A. Órfão,et al.  Myelodysplastic syndrome: a search for minimal diagnostic criteria. , 1999, Leukemia research.

[10]  P. Helft.  Necessary collusion: prognostic communication with advanced cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[12]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Oosterveld,et al.  The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups , 2003, British journal of haematology.

[14]  A. Hagemeijer,et al.  Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. , 1995, Leukemia.

[15]  D. Neuberg,et al.  Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. , 2003, Leukemia research.

[16]  D. Golde,et al.  Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia , 2000, Current oncology reports.

[17]  Yu Shen,et al.  Myelodysplastic syndrome is not merely "preleukemia". , 2002, Blood.

[18]  L. Degos.  John Hughes Bennett, Rudolph Virchow... and Alfred Donné: the first description of leukemia. , 2001, The hematology journal : the official journal of the European Haematology Association.

[19]  D. Galton.  The myelodysplastic syndromes. , 1987, Clinical and laboratory haematology.

[20]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[21]  M. Andersen,et al.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.

[22]  L. Shih,et al.  Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia , 2004, Leukemia.

[23]  G. Tricot.  Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. , 1992, Leukemia research.

[24]  T. Lynch,et al.  Fear of death. , 2005, The oncologist.

[25]  H. Deeg.  Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). , 2005, Hematology. American Society of Hematology. Education Program.

[26]  Eva Steliarova-Foucher,et al.  International Classification of Childhood Cancer, third edition , 2005, Cancer.

[27]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[28]  S. Horiike,et al.  Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. , 1996, Leukemia.

[29]  G. Piller.  Leukaemia – a brief historical review from ancient times to 1950 , 2001, British journal of haematology.

[30]  P. Wiernik,et al.  Neoplastic Diseases of the Blood , 1991 .

[31]  R. Frankel,et al.  The doctor-patient relationship and malpractice. Lessons from plaintiff depositions. , 1994, Archives of internal medicine.

[32]  L O JACOBSON,et al.  Preleukemic acute human leukemia. , 1953, Journal of the American Medical Association.

[33]  D. Head.  Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful? , 2002, Current opinion in oncology.

[34]  P. N. Rao,et al.  Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. , 1996, Leukemia research.

[35]  D. Head.  Problematic WHO Reclassification of Myelodysplastic Syndromes , 2000 .

[36]  U. Germing,et al.  The 5q- syndrome. , 2008, Cancer treatment and research.

[37]  P. Greenberg,et al.  Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study , 2005 .

[38]  J. Bourhis,et al.  Clonality in myelodysplastic syndromes. , 1994, Leukemia & lymphoma.

[39]  D. Steensma,et al.  Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. , 2005, Mayo Clinic proceedings.

[40]  J. Bennett.  A comparative review of classification systems in myelodysplastic syndromes (MDS). , 2005, Seminars in oncology.

[41]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[42]  P. Duesberg,et al.  Genetic instability of cancer cells is proportional to their degree of aneuploidy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Taniwaki,et al.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.

[44]  Noam Chomsky,et al.  The Logical Structure of Linguistic Theory , 1975 .

[45]  M. Cazzola,et al.  Myelodysplastic syndromes--coping with ineffective hematopoiesis. , 2005, The New England journal of medicine.

[46]  T. Naruse,et al.  Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X‐linked restriction fragment length polymorphisms , 1993, British journal of haematology.

[47]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[48]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[49]  J. Boultwood,et al.  Clonality in the Myelodysplastic Syndromes , 2001, International journal of hematology.

[50]  B. Bain.  Di guglielmo and his syndromes , 2003, British journal of haematology.

[51]  M. Slovak,et al.  Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. , 2003, American journal of clinical pathology.

[52]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  D. Steensma,et al.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. , 2003, Leukemia research.

[54]  M. Slovak,et al.  Prognostic Impact of Acute Myeloid Leukemia Classification , 2003 .

[55]  J. Hamilton‐paterson.  Pre-leukaemic anaemia. , 1949, Acta haematologica.

[56]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[57]  O. Haas,et al.  Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems , 2001, Annals of Hematology.

[58]  R. Kaufman,et al.  Smoldering acute leukemia. , 1963, The New England journal of medicine.

[59]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[60]  K. Miller,et al.  Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome , 2002, American journal of hematology.

[61]  J. Bennett,et al.  The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. , 2005, Current hematology reports.

[62]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[63]  H. Heimpel,et al.  Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. , 1989, Blood.

[64]  E. Estey,et al.  Molecular Pathogenesis of MDS. , 2005, Hematology. American Society of Hematology. Education Program.